The substantial interindividual variability in SFN bioavailability, driven by differences in gut microbiota composition and GST polymorphisms, necessitates personalized dosing strategies (100, 101)
However, results can vary, and no single treatment works for everyone
Obesity Trials: Clinical trials showed consistent weight loss in obese subjects over 12 weeks with no marked insulin sensitivity interruption
The comparative perspective provided in Table 3 is fairly beneficial for clinicians, researchers as well as policymakers to choose the right antioxidant approach concerning different clinical contexts
By 104 weeks, approximately 77% of SELECT patients on dose were receiving the target semaglutide 2.4 mg weekly dose, which is lower than the corresponding proportion of patients in STEP 1 (89.6% were receiving the target dose at week 68) 14,21
Suitable for both hair and beard care